Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes (Q34469377)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes (English)

1 reference

Europe PubMed Central

2 August 2017

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Urs A Boelsterli

1

1 reference

Europe PubMed Central

2 August 2017

Marc Bedoucha

2

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

1 January 2002

1 reference

Europe PubMed Central

2 August 2017

Biochemical Pharmacology

1 reference

Europe PubMed Central

2 August 2017

63

1 reference

Europe PubMed Central

2 August 2017

1-10

1 reference

Europe PubMed Central

2 August 2017

1

1 reference

Europe PubMed Central

2 August 2017

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

The organization, promoter analysis, and expression of the human PPARgamma gene

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Down regulation of peroxisome proliferator-activated receptorgamma expression by inflammatory cytokines and its reversal by thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

PPAR gamma and the treatment of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Troglitazone action is independent of adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Troglitazone: a review of its use in the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Potential new treatments for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and beta-oxidation in fructose-fed rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Troglitazone induces expression of PPARgamma in liver

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Steatohepatitis: a tale of two "hits"?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Induction of immediate early genes and apoptosis after ischemia/reperfusion in fatty liver rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Peroxisome proliferator activator receptor-gamma agonists and 15-deoxy-Delta(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Regulation of TRAIL-induced apoptosis by transcription factors

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Peroxisome proliferator-activated receptors and hepatic stellate cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Body composition and hepatic steatosis as precursors for fibrotic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Troglitazone exhibits immunomodulatory activity on the cytokine production of activated human lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Peroxisome proliferator-activated receptor-gamma ligands inhibit nitric oxide synthesis in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Troglitazone prevents fatty changes of the liver in obese diabetic rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900817-6

7 January 2021

Identifiers

10.1016/S0006-2952(01)00817-6

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34469377&oldid=1981034960"